Our HIV research agenda has to address the world outside of a clinical trial, vaccine researcher Stephaun E. Wallace, Ph.D., argues.
April 18, 2019: lamivudine/raltegravir for PrEP; feminizing hormone may impact PrEP efficacy; why TAF has a better renal profile than TDF; the role of internet dating in HIV incidence trends.
Project PrIDE demonstration studies in New York and Houston show that properly funded and well-designed outreach programs can impact a city's ability to provide better HIV services for underserved populations.
This study identified some information about transgender women's sexual networks in Los Angeles. But activists worry about privacy and the potential that the surveillance method will be used in HIV criminalization cases.
New data from CDC show that rates of HIV infection among transgender women in the U.S. are lower than previous estimates, but still, nearly 45% of black transgender women are living with HIV.
The findings mark a crucial point in the history of PrEP delivery among trans women, as they offer clarity for health care providers, PrEP outreach campaigns, and trans women using estradiol as feminizing hormone therapy.
Many trans women living with HIV may contract the virus because they or their sexual partners are intravenous drug users (IDU), finds a new study.
A new provider training centralizes the lived experiences of black gay and bisexual men, and transgender people. Heather Boerner takes an in-depth look.
The more than 300 transgender women in the pivotal iPrEx pre-exposure prophylaxis (PrEP) trial had similar overall HIV infection rates whether they were randomized to take tenofovir/emtricitabine (Truvada) or placebo, but those with drug levels indic...